Abstract:Purpose: The clinical use of paclitaxel (PTX) in cancer treatment is limited by its poor water solubility, significant toxicity, and adverse effects. This study aimed to propose a straightforward and efficient approach to enhance PTX loading and stability, thereby offering insights for targeted therapy against tumors. Patients and methods: We synthesized a paclitaxel palmitate (PTX-PA) prodrug by conjugating palmitic acid (PA) to PTX and encapsulating it into liposomal vehicles using a nano delivery system. Subsequently, we investigated the in vitro and in vivo performance as well as the underlying mechanisms of PTX-PA liposomes (PTX-PA-L). Results: PTX had a remarkable antitumor effect in vivo and significantly decreased the myelosuppressive toxicity of PTX. Moreover, the introduction of PA increased the lipid solubility of PTX, forming a phospholipid bilayer as a membrane stabilizer, prolonging the circulation time of the drug and indirectly increasing the accumulation of liposomes at the tumor site. Our in vivo imaging experiments demonstrated that PTX-PA-L labeled with DiR has greater stability in vivo than blank liposomes and that PTX-PA-L can target drugs to the tumor site and efficiently release PTX to exert antitumor effects. In a mouse model, the concentration of PTX at the tumor site in the PTX-PA-L group was approximately twofold greater than that of Taxol. However, in a nude mouse model, the concentration of PTX at the tumor site in the PTX-PA-L group was only approximately 0.8-fold greater than that of Taxol. Furthermore, the originally observed favorable pharmacodynamics in normal mice were reversed following immunosuppression. This may be caused by differences in esterase distribution and immunity. Conclusion: This prodrug technology combined with liposomes is a simple and effective therapeutic strategy with promising developmental prospects in tumor-targeted therapy owing to its ability to convert PTX into a long-circulating nano drug with low toxicity, high pharmacodynamics, and good stability in vivo.

Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.

Well-Defined Redox-Sensitive Polyethene Glycol–Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting

Enhancement of Antitumor Efficacy of Paclitaxel-Loaded PEGylated Liposomes by N,N-Dimethyl Tertiary Amino Moiety in Pancreatic Cancer

Synthesis of Ph-Sensitive, Water-Soluble Paclitaxel Prodrugs Based on Norbornene-Functional Polylactide by Copper-Free Click Chemistry

Enhanced in vivo Stability and Antitumor Efficacy of PEGylated Liposomes of Paclitaxel Palmitate Prodrug

Development And Evaluation Of A Novel Tpgs-Mediated Paclitaxel-Loaded Plga-Mpeg Nanoparticle For The Treatment Of Ovarian Cancer

Acetal-linked paclitaxel prodrug micellar nanoparticles as a versatile and potent platform for cancer therapy.

Porphyrin Centered Paclitaxel Tetrameric Prodrug Nanoassemblies as Tumor‐Selective Theranostics for Synergized Breast Cancer Therapy

Synthesis, Biological Evaluation and Low-Toxic Formulation Development of Glycosylated Paclitaxel Prodrugs

Synthesis and Characterization of a New Multifunctional Polymeric Prodrug Paclitaxel–polyphosphoester–folic Acid for Targeted Drug Delivery

Paclitaxel prodrug-encapsulated polypeptide micelles with redox/pH dual responsiveness for cancer chemotherapy

Synthetic Paclitaxel-Octreotide Conjugate Reversing the Resistance of A2780/Taxol to Paclitaxel in Xenografted Tumor in Nude Mice

A Novel Lanreotide-Encoded Micelle System Targets Paclitaxel To The Tumors With Overexpression Of Somatostatin Receptors

Enzyme-Sensitive and Amphiphilic PEGylated Dendrimer-Paclitaxel Prodrug-Based Nanoparticles for Enhanced Stability and Anticancer Efficacy

Self-Assembled Disulfide Bond Bearing Paclitaxel-Camptothecin Prodrug Nanoparticle for Lung Cancer Therapy

Redox-Responsive Disulfide Bond-Bridged mPEG-PBLA Prodrug Micelles for Enhanced Paclitaxel Biosafety and Antitumor Efficacy

Well-defined Polymer-Drug Conjugate Engineered with Redox and Ph-Sensitive Release Mechanism for Efficient Delivery of Paclitaxel.

Redox-responsive Prodrug for Improving Oral Bioavailability of Paclitaxel Through Bile Acid Transporter-Mediated Pathway.

Enhanced transcytosis and therapeutic efficacy of paclitaxel nanoparticles: Pyridylboronic acid modification and sialic acid targeting

Octreotide-conjugated PAMAM for Targeted Delivery to Somatostatin Receptors Over-Expressed Tumor Cells

Synthesis and Biological Evaluation of Paclitaxel and Vorinostat Co-Prodrugs for Overcoming Drug Resistance in Cancer Therapy in Vitro.